Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Surgery
Published in: Journal of Gastrointestinal Surgery 6/2015

01-06-2015 | Review Article

Benign Solid Tumors of the Liver: Management in the Modern Era

Authors: Georgios Antonios Margonis, Aslam Ejaz, Gaya Spolverato, Neda Rastegar, Robert Anders, Ihab R. Kamel, Timothy M. Pawlik

Published in: Journal of Gastrointestinal Surgery | Issue 6/2015

Login to get access

Abstract

Background

Recently, there has been a growing interest in solid benign liver tumors as the understanding of the pathogenesis and molecular underpinning of these lesions continues to evolve. We herein provide an evidence-based review of benign solid liver tumors with particular emphasis on the diagnosis and management of such tumors.

Methods

A search of all available literature on benign hepatic tumors through a search of the MEDLINE/PubMed electronic database was conducted.

Results

New diagnostic and management protocols for benign liver tumors have emerged, as well as new insights into the molecular pathogenesis. In turn, these data have spawned a number of new studies seeking to correlate molecular, clinicopathological, and clinical outcomes for benign liver tumors. In addition, significant advances in surgical techniques and perioperative care have reduced the morbidity and mortality of liver surgery. Despite current data that supports conservative management for many patients with benign liver tumors, patients with severe preoperative symptomatic disease seem to benefit substantially from surgical treatment based on quality of life data.

Conclusion

Future studies should seek to further advance our understanding of the underlying pathogenesis and natural history of benign liver tumors in order to provide clinicians with evidence-based guidelines to optimize treatment of patients with these lesions.
Appendix
Available only for authorised users
Literature
1.
Rebouissou S, Bioulac-Sage P and Zucman-Rossi J: Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol, 2008. 48(1): p. 163–70.CrossRefPubMed
2.
Zucman-Rossi J, Jeannot E, Nhieu JT, et al.: Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology, 2006. 43(3): p. 515–24.CrossRefPubMed
3.
4.
Reddy KR, Kligerman S, Levi J, et al.: Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg, 2001. 67(2): p. 173–8.PubMed
5.
6.
Gemer O, Moscovici O, Ben-Horin CL, et al.: Oral contraceptives and liver hemangioma: a case–control study. Acta Obstet Gynecol Scand, 2004. 83(12): p. 1199–201.CrossRefPubMed
7.
Glinkova V, Shevah O, Boaz M, Levine A, and Shirin H: Hepatic haemangiomas: possible association with female sex hormones. Gut, 2004. 53(9): p. 1352–5.CrossRefPubMedCentralPubMed
8.
Saegusa T, Ito K, Oba N, et al.: Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med, 1995. 34(3): p. 207–11.CrossRefPubMed
9.
10.
Xiao X, Hong L and Sheng M: Promoting effect of estrogen on the proliferation of hemangioma vascular endothelial cells in vitro. J Pediatr Surg, 1999. 34(11): p. 1603–5.CrossRefPubMed
11.
Buell JF, Tranchart H, Cannon R and Dagher I: Management of benign hepatic tumors. Surg Clin North Am, 2010. 90(4): p. 719–35.CrossRefPubMed
12.
Etemadi A, Golozar A, Ghassabian A, et al.: Cavernous hemangioma of the liver: factors affecting disease progression in general hepatology practice. Eur J Gastroenterol Hepatol, 2011. 23(4): p. 354–8.CrossRefPubMedCentralPubMed
13.
Terkivatan T, Vrijland WW, Den Hoed PT, et al.: Size of lesion is not a criterion for resection during management of giant liver haemangioma. Br J Surg, 2002. 89(10): p. 1240–4.CrossRefPubMed
14.
Hasan HY, Hinshaw JL, Borman EJ, et al.: Assessing Normal Growth of Hepatic Hemangiomas During Long-term Follow-up. JAMA Surg, 2014.
15.
Kasabach HH and Merritt KK: Capillary hemangioma with extensive purpura: report of a case. American Journal of Diseases of Children, 1940. 59(5): p. 1063–1070.CrossRef
16.
Aiura K, Ohshima R, Matsumoto K, et al.: Spontaneous rupture of liver hemangioma: risk factors for rupture. J Hepatobiliary Pancreat Surg, 1996. 3(3): p. 308–312.CrossRef
17.
Jain V, Ramachandran V, Garg R, et al.: Spontaneous rupture of a giant hepatic hemangioma–sequential management with transcatheter arterial embolization and resection. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 2010. 16(2): p. 116.CrossRef
18.
Beatty JS, Mitchell JW, Holsten SB and Ferdinand C: Traumatic rupture of a previously undiagnosed giant hepatic hemangioma. The American surgeon, 2013. 79(9): p. 314–315.
19.
Gilon D, Slater PE and Benbassat J: Can decision analysis help in the management of giant hemangioma of the liver? J Clin Gastroenterol, 1991. 13(3): p. 255–8.CrossRefPubMed
20.
Chen ZY, Qi QH and Dong ZL: Etiology and management of hemorrhage in spontaneous liver rupture: a report of 70 cases. World J Gastroenterol, 2002. 8(6): p. 1063–6.PubMed
21.
Caseiro-Alves F, Brito J, Araujo AE, et al.: Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. European radiology, 2007. 17(6): p. 1544–1554.CrossRefPubMed
22.
Baer HU, Dennison AR, Mouton W, et al.: Enucleation of giant hemangiomas of the liver. Technical and pathologic aspects of a neglected procedure. Ann Surg, 1992. 216(6): p. 673–6.CrossRefPubMedCentralPubMed
23.
Farges O, Daradkeh S and Bismuth H: Cavernous hemangiomas of the liver: are there any indications for resection. World journal of surgery, 1995. 19(1): p. 19–24.CrossRefPubMed
24.
Yoon SS, Charny CK, Fong Y, et al.: Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg, 2003. 197(3): p. 392–402.CrossRefPubMed
25.
Weimann A, Ringe B, Klempnauer J, et al.: Benign liver tumors: differential diagnosis and indications for surgery. World J Surg, 1997. 21(9): p. 983–90; discussion 990–1.CrossRefPubMed
26.
Belghiti J, Cauchy F, Paradis V and Vilgrain V: Diagnosis and management of solid benign liver lesions. Nat Rev Gastroenterol Hepatol, 2014.
27.
Xiao-Hui F, Chun Hung LE, Xiao-Ping Y, et al.: Enucleation of liver hemangiomas: is there a difference in surgical outcomes for centrally or peripherally located lesions? The American Journal of Surgery, 2009. 198(2): p. 184–187.CrossRef
28.
Loss M, Zulke C, Obed A, Stoltzing O, and Schlitt HJ: Surgical therapy of benign liver tumors. Chirurg, 2008. 79(8): p. 722–8.CrossRefPubMed
29.
Schnelldorfer T, Ware AL, Smoot R, et al.: Management of giant hemangioma of the liver: resection versus observation. J Am Coll Surg, 2010. 211(6): p. 724–30.CrossRefPubMed
30.
Erdogan D, Busch OR, Van Delden OM, et al.: Management of liver hemangiomas according to size and symptoms. Journal of gastroenterology and hepatology, 2007. 22(11): p. 1953–1958.CrossRefPubMed
31.
32.
Bioulac-Sage P, Laumonier H, Rullier A, et al.: Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int, 2009. 29(3): p. 459–65.CrossRefPubMed
33.
Maillette de Buy Wenniger L, Terpstra V and Beuers U: Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg, 2010;27(1):24–31.CrossRefPubMed
34.
Bioulac-Sage P, Cubel G, Balabaud C and Zucman-Rossi J: Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Seminars in liver disease, 2011. 31: p. 091–103.CrossRef
35.
Wanless IR, Mawdsley C and Adams R: On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology, 1985. 5(6): p. 1194–1200.CrossRefPubMed
36.
Suri C, Jones PF, Patan S, et al.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 1996. 87(7): p. 1171–80.CrossRefPubMed
37.
Ijichi H, Taketomi A, Yoshizumi T, et al.: Hyperbaric oxygen induces vascular endothelial growth factor and reduces liver injury in regenerating rat liver after partial hepatectomy. J Hepatol, 2006. 45(1): p. 28–34.CrossRefPubMed
38.
Navarro AP, Gomez D, Lamb CM, Brooks A, and Cameron IC: Focal nodular hyperplasia: a review of current indications for and outcomes of hepatic resection. HPB (Oxford), 2014. 16(6): p. 503–11.CrossRef
39.
Nguyen BN, Flejou JF, Terris B, Belghiti J, and Degott C: Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol, 1999. 23(12): p. 1441–54.CrossRefPubMed
40.
Shortell C and Schwartz S: Hepatic adenoma and focal nodular hyperplasia. Surgery, gynecology & obstetrics, 1991. 173(5): p. 426–431.
41.
Aldinger K, Ben-Menachem Y and Whalen G: Focal nodular hyperplasia of the liver associated with high-dosage estrogens. Archives of internal medicine, 1977. 137(3): p. 357–359.CrossRefPubMed
42.
Fechner RE: Benign hepatic lesions and orally administered contraceptives: A report of seven cases and a critical analysis of the literature. Human pathology, 1977. 8(3): p. 255–268.CrossRefPubMed
43.
Mathieu D, Kobeiter H, Maison P, et al.: Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology, 2000. 118(3): p. 560–564.CrossRefPubMed
44.
Gaffey MJ, Iezzoni JC and Weiss LM: Clonal analysis of focal nodular hyperplasia of the liver. Am J Pathol, 1996. 148(4): p. 1089–96.PubMedCentralPubMed
45.
D’Halluin V, Vilgrain V, Pelletier G, et al.: Natural history of focal nodular hyperplasia. A retrospective study of 44 cases. Gastroenterol Clin Biol, 2001. 25(11): p. 1008–10.PubMed
46.
Di Stasi M, Caturelli E, De Sio I, et al.: Natural history of focal nodular hyperplasia of the liver: an ultrasound study. J Clin Ultrasound, 1996. 24(7): p. 345–50.CrossRefPubMed
47.
Palmucci S: Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. World J Hepatol, 2014. 6(7): p. 477–85.CrossRefPubMedCentralPubMed
48.
Bashir MR, Gupta RT, Davenport MS, et al.: Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging, 2013. 37(2): p. 398–406.CrossRefPubMed
49.
KG I: Benign tumors of the liver. Medical Clinics of North America 59 (4): 995–1013. July 1975, 1975.
50.
51.
Paradis V, Benzekri A, Dargere D, et al.: Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology, 2004. 126(5): p. 1323–9.CrossRefPubMed
52.
Galanski M, Jördens S and Weidemann J: Diagnosis and differential diagnosis of benign liver tumors and tumor-like lesions. Chirurg, 2008. 79(8): p. 707–721.CrossRefPubMed
53.
Skalický T, Treska V, Sutnar A, et al.: Surgical treatment of benign liver tumours-indications and results. Zentralblatt fur Chirurgie, 2009. 134(2): p. 141–144.
54.
Ehrl D, Rothaug K, Herzog P, Hofer B, and Rau H-G: “Incidentaloma” of the Liver: Management of a Diagnostic and Therapeutic Dilemma. HPB Surgery, 2012. 2012.
55.
Mezhir JJ, Fourman LT, Do RK, et al.: Changes in the management of benign liver tumours: an analysis of 285 patients. HPB (Oxford), 2013. 15(2): p. 156–63.CrossRef
56.
Perrakis A, Demir R, Muller V, et al.: Management of the focal nodular hyperplasia of the liver: evaluation of the surgical treatment comparing with observation only. Am J Surg, 2012. 204(5): p. 689–96.CrossRefPubMed
57.
Jeannot E, Wendum D, Paye F, et al.: Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. J Hepatol, 2006. 45(6): p. 883–6.CrossRefPubMedCentralPubMed
58.
Rooks JB, Ory HW, Ishak KG, et al.: Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA, 1979. 242(7): p. 644–8.CrossRefPubMed
59.
Klatskin G: Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology, 1977. 73(2): p. 386–394.PubMed
60.
Baum J, Bookstein J, Holtz F and Klein E: Possible association between benign hepatomas and oral contraceptives. The Lancet, 1973. 302(7835): p. 926–929.CrossRef
61.
Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, and Thung SN: Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol, 2013. 2013: p. 604860.PubMedCentralPubMed
62.
Carrasco D, Barrachina M, Prieto M and Berenguer J: Clomiphene citrate and liver-cell adenoma. N Engl J Med, 1984. 310(17): p. 1120–1.CrossRefPubMed
63.
Dokmak S, Paradis V, Vilgrain V, et al.: A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology, 2009. 137(5): p. 1698–1705.CrossRefPubMed
64.
Vázquez J, Jaime J and Marigil MA: Liver-cell adenoma in an epileptic man on barbiturates. 1989.
65.
Nime F, Pickren JW, Vana J, et al.: The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer, 1979. 44(4): p. 1481–9.CrossRefPubMed
66.
Rosenberg L: The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception, 1991. 43(6): p. 643–652.CrossRefPubMed
67.
Leese T, Farges O and Bismuth H: Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg, 1988. 208(5): p. 558–64.CrossRefPubMedCentralPubMed
68.
Bioulac-Sage P, Taouji S, Possenti L and Balabaud C: Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int, 2012. 32(8): p. 1217–21.CrossRefPubMed
69.
van Aalten SM, de Man RA, JN IJ and Terkivatan T: Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg, 2012. 99(7): p. 911–6.
70.
Deneve JL, Pawlik TM, Cunningham S, et al.: Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol, 2009. 16(3): p. 640–8.CrossRefPubMed
71.
Bieze M, Phoa SS, Verheij J, van Lienden KP, and van Gulik TM: Risk factors for bleeding in hepatocellular adenoma. Br J Surg, 2014. 101(7): p. 847–55.CrossRefPubMed
72.
van Aalten SM, Verheij J, Terkivatan T, et al.: Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol, 2011. 55(1): p. 120–5.CrossRefPubMed
73.
Farges O, Ferreira N, Dokmak S, et al.: Changing trends in malignant transformation of hepatocellular adenoma. Gut, 2011. 60(1): p. 85–9.CrossRefPubMed
74.
Stoot JH, Coelen RJ, De Jong MC and Dejong CH: Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB, 2010. 12(8): p. 509–522.CrossRefPubMedCentralPubMed
75.
Micchelli ST, Vivekanandan P, Boitnott JK, et al.: Malignant transformation of hepatic adenomas. Mod Pathol, 2008. 21(4): p. 491–7.CrossRefPubMed
76.
Kim DH, Kim SU, Nam DH, et al.: A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. The Korean journal of internal medicine, 2009. 24(2): p. 147–152.CrossRefPubMedCentralPubMed
77.
Velazquez I and Alter BP: Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol, 2004. 77(3): p. 257–67.CrossRefPubMed
78.
Gorayski P, Thompson CH, Subhash H and Thomas AC: Hepatocellular carcinoma associated with recreational anabolic steroid use. British journal of sports medicine, 2008. 42(1): p. 74–75.CrossRefPubMed
79.
Franco LM, Krishnamurthy V, Bali D, et al.: Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis, 2005. 28(2): p. 153–62.CrossRefPubMed
80.
Dokmak S, Cauchy F and Belghiti J: Resection, transplantation and local regional therapies for liver adenomas. Expert Rev Gastroenterol Hepatol, 2014: p. 1–8.
81.
Bioulac-Sage P, Laumonier H, Couchy G, et al.: Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology, 2009. 50(2): p. 481–9.CrossRefPubMed
82.
Balabaud C, Al-Rabih WR, Chen P-J, et al.: Focal nodular hyperplasia and hepatocellular adenoma around the world viewed through the scope of the immunopathological classification. International journal of hepatology, 2013. 2013.
83.
Stoot J, Van Der Linden E, Terpstra O and Schaapherder A: Life-saving therapy for haemorrhaging liver adenomas using selective arterial embolization. British journal of surgery, 2007. 94(10): p. 1249–1253.CrossRefPubMed
84.
Erdogan D, Busch OR, van Delden OM, et al.: Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int, 2006. 26(4): p. 433–8.CrossRefPubMed
85.
Marini P, Vilgrain V and Belghiti J: Management of spontaneous rupture of liver tumours. Dig Surg, 2002. 19(2): p. 109–13.CrossRefPubMed
86.
Terkivatan T, de Wilt JH, de Man RA, et al.: Treatment of ruptured hepatocellular adenoma. Br J Surg, 2001. 88(2): p. 207–9.CrossRefPubMed
87.
van Vledder MG, van Aalten SM, Terkivatan T, et al.: Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol, 2011. 22(6): p. 787–93.CrossRefPubMed
88.
Karkar AM, Tang LH, Kashikar ND, et al.: Management of hepatocellular adenoma: comparison of resection, embolization and observation. HPB, 2013. 15(3): p. 235–243.CrossRefPubMedCentralPubMed
89.
90.
Delgado J, Jaramillo D, Ho-Fung V, Fisher MJ, and Anupindi SA: MRI features of plexiform neurofibromas involving the liver and pancreas in children with neurofibromatosis type 1. Clin Radiol, 2014. 69(6): p. e280-4.CrossRefPubMed
91.
Kneuertz PJ, Marsh JW, de Jong MC, et al.: Improvements in quality of life after surgery for benign hepatic tumors: Results from a dual center analysis. Surgery, 2012. 152(2): p. 193–201.CrossRefPubMed
92.
Kamphues C, Engel S, Denecke T, et al.: Safety of liver resection and effect on quality of life in patients with benign hepatic disease: single center experience. BMC Surg, 2011. 11: p. 16.CrossRefPubMedCentralPubMed
93.
Nault JC and Zucman Rossi J: Molecular classification of hepatocellular adenomas. International journal of hepatology, 2013. 2013.
Metadata
Title
Benign Solid Tumors of the Liver: Management in the Modern Era
Authors
Georgios Antonios Margonis
Aslam Ejaz
Gaya Spolverato
Neda Rastegar
Robert Anders
Ihab R. Kamel
Timothy M. Pawlik
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 6/2015
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-014-2723-x

Other articles of this Issue 6/2015

Journal of Gastrointestinal Surgery 6/2015 Go to the issue

GI Image

Bouveret’s Syndrome Resulting in Gallstone Ileus

How I do it

The Surgical Management of Achalasia in the Morbid Obese Patient

Letter to the Editor

Perioperative Blood Transfusion and Long-Term Outcomes After Resection of Hilar Cholangiocarcinoma

2014 SSAT Plenary Presentation

Do Adverse Childhood Experiences Affect Surgical Weight Loss Outcomes?

Original Article

Chronic Abdominal Syndrome Due to Nervous Compression. Study of 100 Cases and Proposed Diagnostic-Therapeutic Algorithm

Review Article

Ex Vivo Resection of Hepatic Neoplasia and Autotransplantation: A Case Report and Review of the Literature